UroGen Pharma Long Term Debt

UroGen Pharma (URGN) currently reports a long-term debt of $190M as of June 2026. That compares with $130M in the prior-year period — up 50.0% year over year. Use the charts on this page to explore UroGen Pharma's long-term debt history and peer comparisons.

UroGen Pharma's long-term debt increased from $130M to $190M — a 50.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

UroGen Pharma reported $190M in long-term debt as of June 2026. That compares with $130M in the prior-year period — up 50.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $190M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for UroGen Pharma, and consider following URGN for alerts when major investors trade the stock.

UroGen Pharma is classified in the Healthcare sector. On long-term debt, it currently shows $190M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing URGN with unrelated industries.